Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Faeth Therapeutics, Inc.SNSE · Entity 5029 | President & PEO | June 10, 2026 | June 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Faeth Therapeutics, Inc.
Report date June 10, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.89 · Expires 2036-06-09 | Direct | 220,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 220,000 · Balance 220,000 F1: The stock option grant was approved by the Issuer's Board of Directors on April 10, 2026, subject to stockholder approval of the 2026 Equity Incentive Plan, which approval was obtained on June 10, 2026. The exercise price reflects the closing price of the Issuer's common stock on April 10, 2026. F2: 25% of the shares subject to the option vest and become exercisable on April 10, 2027, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter, such that the option is fully vested on the fourth anniversary of the vesting commencement date, or April 10, 2030, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option grant was approved by the Issuer's Board of Directors on April 10, 2026, subject to stockholder approval of the 2026 Equity Incentive Plan, which approval was obtained on June 10, 2026. The exercise price reflects the closing price of the Issuer's common stock on April 10, 2026.
F2: 25% of the shares subject to the option vest and become exercisable on April 10, 2027, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter, such that the option is fully vested on the fourth anniversary of the vesting commencement date, or April 10, 2030, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 13, 2026 01:12 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (right to buy) · Derivative | 220,000 | $0.00 Strike: $29.89 | $0.00 |
DisclosureSEC source: 0002097951-26-000001 · form4-06132026_010653.xml · derivative · entry 1 Gerry Christopher · CIK 0002097951 · President & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2036-06-09 F1 · date: The stock option grant was approved by the Issuer's Board of Directors on April 10, 2026, subject to stockholder approval of the 2026 Equity Incentive Plan, which approval was obtained on June 10, 2026. The exercise price reflects the closing price of the Issuer's common stock on April 10, 2026. F2 · derivative.exercise_date: 25% of the shares subject to the option vest and become exercisable on April 10, 2027, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter, such that the option is fully vested on the fourth anniversary of the vesting commencement date, or April 10, 2030, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.